Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance

• Type of Material: Article
• Authors: Theresa A. Boyle, H. Lee Moffitt Cancer Center & Research Institute; Farah K. Khalil, University of South Florida; Mari Mino-Kenudson, Massachusetts General Hospital; Gabriel Sica, Emory University; Andre L. Moreira, New York University; Lynette M. Sholl, Brigham and Women’s Hospital; Mirna Z. Knight, Metropolitan Pathologists; Liping Zhang, Tongji University; James Saller, H. Lee Moffitt Cancer Center & Research Institute; Marileila Varella-Garcia, University of Colorado; Lynne D. Berry, Vanderbilt-Ingram Cancer Center; Heidi Chen, Vanderbilt-Ingram Cancer Center; Kim E. Ellison, University of Colorado; Christopher J. Rivard, University of Colorado; Kelly Kugler, Lung Cancer Mutation Consortium; Ignacio I. Wistuba, University of Texas M.D. Anderson Cancer Center; Junya Fujimoto, University of Texas M.D. Anderson Cancer Center; David J. Kwiatkowski, Brigham and Women’s Hospital; Paul A. Bunn, University of Colorado; Mark G. Kris, Memorial Sloan Kettering Cancer Center; Eric B. Haura, H. Lee Moffitt Cancer Center & Research Institute; Fred R. Hirsch, University of Colorado
• Language: English
• Date: 2020-10-01
• Publisher: Lippincott, Williams & Wilkins
• Publication Version: Final Published Version
• Copyright Statement: © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1097/PAI.0000000000000810
• Title of Journal or Parent Work: APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
• Volume: 28
• Issue: 9
• Start Page: 669
• End Page: 677
• Keywords: histology score (H-score); mesenchymal-epithelial transition (MET) receptor; reproducibility; immunohistochemistry; lung cancer
• Research Categories: Health Sciences, Oncology; Health Sciences, Immunology; Chemistry, General

Abstract

Overexpression of the mesenchymal-epithelial transition (MET) receptor, a receptor tyrosine kinase, can propel the growth of cancer cells and portends poor prognoses for patients with lung cancer. Evaluation of MET by immunohistochemistry is challenging, with MET protein overexpression varying from 20% to 80% between lung cancer cohorts. Clinical trials using MET protein expression to select patients have also reported a wide range of positivity rates and outcomes.